Holen Sie sich die Stockscreener-App
419.83
0.26%
-1.08
Handel nachbörslich:
419.39
-0.44
-0.10%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$420.91
Offen:
$421.5
24-Stunden-Volumen:
422.85K
Relative Volume:
0.83
Marktkapitalisierung:
$34.38B
Einnahmen:
$3.84B
Nettoeinkommen (Verlust:
$866.24M
KGV:
42.84
EPS:
9.8
Netto-Cashflow:
$792.60M
1W Leistung:
-3.99%
1M Leistung:
-8.28%
6M Leistung:
-22.75%
1J Leistung:
-9.46%
1-Tages-Spanne:
$418.95
$424.05
1-Wochen-Bereich:
$408.95
$436.75
52-Wochen-Spanne:
$404.74
$583.39
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
CIBC Asset Management Inc Acquires 1,338 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Comgest Global Investors S.A.S. Buys 12,353 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
ING Groep NV Trims Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
IDEXX Laboratories Sees Unusually High Options Volume (NASDAQ:IDXX) - MarketBeat
First Week of July 2025 Options Trading For Idexx Laboratories (IDXX) - Nasdaq
IDEXX Laboratories (NASDAQ:IDXX) shareholders have earned a 10% CAGR over the last five years - Yahoo Finance
KBC Group NV Grows Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Victory Capital Management Inc. - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Sumitomo Mitsui Trust Group Inc. - MarketBeat
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Entropy Technologies LP Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Jonathan W. Ayers Resigns from IDEXX Laboratories (IDXX) Board o - GuruFocus.com
Idexx Laboratories Announces CEO Jonathan Ayers’ Resignation - TipRanks
ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents - Business Wire
Crystal Rock Capital Management Has $4.55 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
2,720 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Versor Investments LP - MarketBeat
IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics?Major Drivers - Smartkarma
IDEXX Laboratories Q3: Weak End-Market Demand Continues - Seeking Alpha
Jensen Investment Management Inc. Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by TimesSquare Capital Management LLC - MarketBeat
Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)? - Yahoo Finance
Villere ST Denis J & Co. LLC Lowers Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories Inc. stock rises Friday, still underperforms market - MarketWatch
Fiera Capital Corp Has $63.52 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Principal Financial Group Inc. Decreases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories, Inc. Updates Earnings Guidance for the Full Year of 2024 - Marketscreener.com
Is IDEXX Laboratories (IDXX) The Best Pet Stock To Invest In According To Analysts? - Insider Monkey
IDEXX Laboratories Inc. stock rises Wednesday, still underperforms market - MarketWatch
IDEXX Laboratories, Inc. Updates Earnings for the Full Year 2024 - Marketscreener.com
Could The Market Be Wrong About IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Its Attractive Financial Prospects? - Yahoo Finance
National Pension Service Raises Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Van ECK Associates Corp Grows Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? - The Motley Fool
IDEXX Laboratories' SWOT analysis: veterinary diagnostics leader faces market shifts - Investing.com Australia
IDEXX Laboratories Inc. stock rises Tuesday, still underperforms market - MarketWatch
Vanguard Group Inc's Strategic Acquisition of IDEXX Laboratories Shares - GuruFocus.com
IDEXX Laboratories (NASDAQ:IDXX) Given "Neutral" Rating at Piper Sandler - MarketBeat
IDEXX Laboratories (NASDAQ:IDXX) Price Target Lowered to $481.00 at Barclays - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Lessened by Capital Investment Services of America Inc. - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
IDEXX stock falls 10% on Q3 revenue miss, lowered guidance - MSN
New York State Common Retirement Fund Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
IDEXX Laboratories (WBO:IDXX) Enterprise Value : €32,027 Mil (As of Nov. 02, 2024) - GuruFocus.com
IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: IDEXX reports solid Q3 growth, revises full-year guidance - Investing.com Australia
Here’s Why Aristotle Focus Growth Strategy Sold IDEXX Laboratories (IDXX) - Insider Monkey
IDEXX Adjusts Revenue Forecast As Pet Care Costs Bite - Finimize
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):